Phase 3 study with imlifidase in anti-GBM antibody disease
Research type
Research Study
Full title
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)
IRAS ID
1005498
Contact name
Melanie Pooler
Contact email
Sponsor organisation
Hansa Biopharma AB
Clinicaltrials.gov Identifier
Research summary
Phase 3 study with imlifidase in anti-GBM antibody disease
REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
22/EM/0197
Date of REC Opinion
10 Oct 2022
REC opinion
Further Information Favourable Opinion